{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=56&state=Alabama", "query": { "state": "Alabama", "city": "Birmingham", "page": 56 }, "page_size": 10 }, "pagination": { "page": 56, "page_size": 10, "total_count": 1975, "total_pages": 198, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=57&state=Alabama&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=55&state=Alabama&page_size=10" }, "source": "local", "last_synced_at": "2026-10-21T19:32:29.797Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07606274", "title": "A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "LMNA-Related Dilated Cardiomyopathy" ], "interventions": [ { "name": "NVC-001 - High Dose", "type": "GENETIC" }, { "name": "NVC-001 - Intermediate Dose", "type": "GENETIC" }, { "name": "NVC-001 - Low Dose", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Nuevocor Pte. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2026-06-16", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-16T19:53:00.023Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07606274" }, { "nct_id": "NCT06580314", "title": "Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "FIGO Stage III Ovarian Cancer 2014", "FIGO Stage IV Ovarian Cancer 2014", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube High Grade Serous Adenocarcinoma", "Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor", "Ovarian Carcinoma", "Ovarian Carcinosarcoma", "Ovarian High Grade Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal Endometrioid Adenocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2025-03-12", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-14T13:34:15.897Z", "location_count": 676, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 458 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06580314" }, { "nct_id": "NCT05999994", "title": "A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adolescent", "Child", "Neoplasms" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "39 Years", "sex": "ALL", "summary": "1 Year to 39 Years" }, "enrollment_count": 105, "start_date": "2020-01-22", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-15T21:42:51.395Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05999994" }, { "nct_id": "NCT04752722", "title": "LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-muscle Invasive Bladder Cancer", "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ", "Superficial Bladder Cancer" ], "interventions": [ { "name": "EG-70 (phase 1)", "type": "DRUG" }, { "name": "EG-70 (phase 2) Master Protocol", "type": "DRUG" }, { "name": "Surfactant Bladder Pre-Rinse and EG-70 (Substudy)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "enGene, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2021-04-22", "completion_date": "2030-10-30", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-14T14:18:55.887Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752722" }, { "nct_id": "NCT04251052", "title": "A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ovarian Carcinoma" ], "interventions": [ { "name": "Bilateral Salpingectomy", "type": "PROCEDURE" }, { "name": "Bilateral Salpingectomy with Oophorectomy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Transvaginal Ultrasound", "type": "PROCEDURE" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "35 Years to 50 Years · Female only" }, "enrollment_count": 1956, "start_date": "2020-09-01", "completion_date": "2047-06-30", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-21T19:32:29.797Z", "location_count": 564, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 372 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04251052" }, { "nct_id": "NCT02780297", "title": "Prospective Research Rare Kidney Stones (ProRKS)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenine Phosphoribosyltransferase Deficiency", "Cystinuria", "Dent Disease", "Hyperoxaluria", "Lowe Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 220, "start_date": "2016-05", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-08T00:14:40.712Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Jacksonville, Florida • Chicago, Illinois + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02780297" }, { "nct_id": "NCT07748858", "title": "Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cardiovascular", "Cardiovascular Disease", "Chronic Kidney Diease", "Chronic Obstructive Pulmonary Disease (COPD)", "Comorbidity", "Diabetes", "Inflammatory Joint Diseases" ], "interventions": [], "intervention_types": [], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "50 Years to 99 Years" }, "enrollment_count": 29, "start_date": "2026-05-01", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-08-07T05:05:44.547Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07748858" }, { "nct_id": "NCT06559150", "title": "A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-cystic Fibrosis Bronchiectasis" ], "interventions": [ { "name": "Nebulized Ensifentrine Suspension; 3 mg", "type": "DRUG" }, { "name": "Nebulized Placebo Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 284, "start_date": "2024-09-11", "completion_date": "2027-09-24", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-04T00:04:31.124Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06559150" }, { "nct_id": "NCT05064709", "title": "Assessment of CCM in HF With Higher Ejection Fraction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diastolic Heart Failure", "Heart Failure", "Heart Failure With Mid Range Ejection Fraction", "Heart Failure With Moderately Reduced Ejection Fraction", "Heart Failure With Preserved Ejection Fraction" ], "interventions": [ { "name": "Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System", "type": "DEVICE" }, { "name": "OPTIMIZER™ Smart Mini System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Impulse Dynamics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1500, "start_date": "2022-02-03", "completion_date": "2029-02-01", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-19T00:18:02.641Z", "location_count": 105, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05064709" }, { "nct_id": "NCT06788756", "title": "L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acute Myeloid Leukaemia (AML)" ], "interventions": [ { "name": "Liposomal Annamycin Injection in combination with Cytarabine Injection", "type": "DRUG" }, { "name": "Liposomal Annamycin for Injection in combination with Cytarabine Injection.", "type": "DRUG" }, { "name": "Placebo in combination with Cytarabine Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Moleculin Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 312, "start_date": "2025-03-12", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-14T03:19:25.022Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Miami, Florida • Augusta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06788756" } ] }